Absci

Q2 FY2026 EarningsQ2 FY26 revenue of $0.32M significantly missed the $0.93M consensus, while GAAP EPS of -$0.21 was slightly below the -$0.20 expected. The primary highlight was the $100M capital raise, including a strategic $40M investment from Eli Lilly, which extends the cash runway into H2 2028. Clinical progress remains on track with positive interim Phase 1 data for ABS-201 and an anticipated interim proof-of-concept readout in H2 2026.